Novel Feeder-Free TIL Expansion Platform Enhances Safety and Efficacy in Immunotherapy

Researchers develop a novel feeder-free TIL expansion platform that reduces high-dose IL-2 reliance, improving safety and efficacy for solid tumor immunotherapy.